[go: up one dir, main page]

WO2005009384A3 - Inhibiteurs de la tyrosine kinase egfr - Google Patents

Inhibiteurs de la tyrosine kinase egfr Download PDF

Info

Publication number
WO2005009384A3
WO2005009384A3 PCT/US2004/023662 US2004023662W WO2005009384A3 WO 2005009384 A3 WO2005009384 A3 WO 2005009384A3 US 2004023662 W US2004023662 W US 2004023662W WO 2005009384 A3 WO2005009384 A3 WO 2005009384A3
Authority
WO
WIPO (PCT)
Prior art keywords
tyrosine kinase
kinase inhibitors
egfr tyrosine
compounds
modulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/023662
Other languages
English (en)
Other versions
WO2005009384A2 (fr
Inventor
Yaron Hadari
Leon M Ii Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone Systems Inc filed Critical ImClone Systems Inc
Publication of WO2005009384A2 publication Critical patent/WO2005009384A2/fr
Publication of WO2005009384A3 publication Critical patent/WO2005009384A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention porte sur des composés qui inhibent, modulent ou régulent des kinases, des compositions qui contiennent des composés inhibant des kinases, et sur des procédés de traitement de maladies et de conditions qui dépendent de la kinase chez des sujets qui ont besoin d'un tel traitement. L'invention porte aussi sur des procédés de fabrication de ces composés qui inhibent, modulent ou régulent les kinases.
PCT/US2004/023662 2003-07-21 2004-07-21 Inhibiteurs de la tyrosine kinase egfr Ceased WO2005009384A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48917603P 2003-07-21 2003-07-21
US60/489,176 2003-07-21
US54768204P 2004-02-24 2004-02-24
US60/547,682 2004-02-24

Publications (2)

Publication Number Publication Date
WO2005009384A2 WO2005009384A2 (fr) 2005-02-03
WO2005009384A3 true WO2005009384A3 (fr) 2005-12-08

Family

ID=34107789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/023662 Ceased WO2005009384A2 (fr) 2003-07-21 2004-07-21 Inhibiteurs de la tyrosine kinase egfr

Country Status (1)

Country Link
WO (1) WO2005009384A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089298A2 (fr) * 2005-02-18 2006-08-24 Attenuon, Llc Derives de diazepine fusionnes pyrimidine et pteridines fusionnees indole
EP2102203B1 (fr) * 2007-04-11 2016-02-17 Merck Sharp & Dohme B.V. Procédé de préparation de benzazépine énantiomorphiquement pure
WO2010040527A1 (fr) * 2008-10-10 2010-04-15 Priaxon Ag Nouveaux composés qui modulent l'activité kinase
CN102690278B (zh) * 2011-03-21 2015-07-15 长春吉大天元化学技术股份有限公司 新颖嘧啶并环化合物作为细胞因子抑制剂
CN103509024B (zh) * 2012-06-28 2015-10-28 上海医药工业研究院 嘧啶并苯并氮杂卓类化合物及其作为抗肿瘤药物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU671271A1 (ru) * 1977-04-27 1982-10-07 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные пиримидо-[4,5- @ ] [1,4]-бензоксазепина и способ их получени

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU671271A1 (ru) * 1977-04-27 1982-10-07 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные пиримидо-[4,5- @ ] [1,4]-бензоксазепина и способ их получени

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEVKOVAKAYA J. ET AL: "Study of Nitrogen- and Oxygen-Containing Heterocycles. 42. Pyrimido[4,5-b]-and pyrido[2,3-b]-1,4-benzoxazepine", KHIMIYA GETEROTSIKLICHESKIKH SOEDINENII, vol. 1, 1985, pages 122 - 125, XP008054762 *
SAFONOVA T.S. ET AL: "Investigation of Nitrogen and Sulfur-Containing Heterocycles. 53* Reactions of 5-Amino-6-Mercapto-Pyrimidines With Derivatives of p-Chloronitrobenzene. Synthesis of a New Heterocyclic System Pyrimido[4,5-b]-1,4-benzothiazepine", CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 37, no. 2, February 2001 (2001-02-01), pages 245 - 250, XP002991598 *
SAFONOVA T.S. ET AL: "Synthesis and Biological Properties of Arylthio-1,2,3-triazole Derivatives", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 37, no. 6, June 2003 (2003-06-01), pages 298 - 305, XP002991597 *

Also Published As

Publication number Publication date
WO2005009384A2 (fr) 2005-02-03

Similar Documents

Publication Publication Date Title
IL171976A0 (en) Indazole, benzisoxazole, and banzisothiazole kinase inhibitors
WO2006050109A3 (fr) Nouveaux inhibiteurs de kinase
WO2007079164A3 (fr) Inhibiteurs de protéines kinases
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
WO2005048953A3 (fr) Derives d'amide utilises comme modulateurs de la kinase
WO2007064797A3 (fr) Inhibiteurs de c-met et leurs utilisations
WO2004089286A3 (fr) Nouveaux composes et compositions utilises comme inhibiteurs de la proteine kinase
AU3113902A (en) Thiazolyl inhibitors of tec family tyrosine kinases
MX2010005950A (es) 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa.
WO2004073653A3 (fr) Methode de traitement de la douleur consistant a administrer un antagoniste du facteur de croissance neuronale ainsi que des medicaments anti-inflammatoires non steroidiens (nsaid) et composition les contenant
WO2003037252A3 (fr) Inhibiteurs de tyrosines kinases
WO2003092595A3 (fr) Inhibiteurs de la tyrosine kinase
WO2006023544A3 (fr) Applications therapeutiques d'inhibiteurs de rtp801
WO2002045652A3 (fr) Inhibiteurs de tyrosine-kinase
WO2006024018A3 (fr) Methodes et compositions pour le traitement de la douleur nociceptive
MXPA06010904A (es) Inhibidores de pirazol cinasa triciclicos.
WO2007067781A3 (fr) Inhibiteurs de proteines kinases
WO2008066755A3 (fr) Inhibiteurs de tyrosine kinase en tant qu'agents anti-kinétolastides et anti-apicomplexes
WO2003015608A3 (fr) Multitherapie pour le traitement du cancer
WO2004030620A3 (fr) Inhibiteurs de tyrosine kinase
MXPA05009151A (es) Inhibidores de cinasa heterociclica.
WO2005007123A3 (fr) Composes modulateurs de pin-1 et methodes d'utilisation associees
WO2004021988A3 (fr) Traitement de la douleur par inhibition de la map kinase p38
WO2003020699A3 (fr) Inhibiteurs de la tyrosine kinase
WO2007016338A3 (fr) Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase